Vivian Shi
Concepts (510)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Dermatitis, Atopic | 51 | 2024 | 92 | 26.360 |
Why?
| Hidradenitis Suppurativa | 52 | 2023 | 56 | 21.140 |
Why?
| Dermatology | 20 | 2022 | 72 | 9.000 |
Why?
| Eczema | 16 | 2022 | 25 | 8.550 |
Why?
| Skin Diseases | 11 | 2022 | 141 | 5.900 |
Why?
| Antibodies, Monoclonal, Humanized | 14 | 2022 | 240 | 5.120 |
Why?
| Skin | 20 | 2023 | 469 | 3.900 |
Why?
| Humans | 177 | 2024 | 54391 | 3.850 |
Why?
| Psoriasis | 8 | 2022 | 43 | 3.630 |
Why?
| Dermatologic Agents | 7 | 2020 | 25 | 3.120 |
Why?
| Immunosuppressive Agents | 9 | 2021 | 248 | 2.680 |
Why?
| Dermatitis, Allergic Contact | 4 | 2022 | 18 | 2.650 |
Why?
| Allergens | 5 | 2022 | 147 | 2.550 |
Why?
| Severity of Illness Index | 22 | 2024 | 1082 | 2.480 |
Why?
| Acne Vulgaris | 6 | 2019 | 21 | 2.370 |
Why?
| Rosacea | 8 | 2020 | 13 | 2.350 |
Why?
| Probiotics | 4 | 2020 | 32 | 2.310 |
Why?
| Emollients | 9 | 2023 | 13 | 2.230 |
Why?
| Complementary Therapies | 3 | 2021 | 31 | 2.200 |
Why?
| Pandemics | 8 | 2021 | 594 | 2.100 |
Why?
| Pruritus | 7 | 2022 | 52 | 1.880 |
Why?
| Health Services Accessibility | 4 | 2021 | 428 | 1.860 |
Why?
| Skin Care | 3 | 2019 | 11 | 1.830 |
Why?
| Patient Education as Topic | 5 | 2021 | 311 | 1.820 |
Why?
| Comprehension | 5 | 2022 | 115 | 1.790 |
Why?
| Health Literacy | 4 | 2022 | 141 | 1.730 |
Why?
| Sunscreening Agents | 3 | 2022 | 6 | 1.710 |
Why?
| Clinical Trials as Topic | 6 | 2020 | 491 | 1.670 |
Why?
| Pneumonia, Viral | 6 | 2020 | 184 | 1.620 |
Why?
| Conjunctivitis | 2 | 2023 | 9 | 1.600 |
Why?
| Coronavirus Infections | 6 | 2020 | 192 | 1.600 |
Why?
| Keratosis, Actinic | 3 | 2021 | 9 | 1.590 |
Why?
| Medicare Part D | 2 | 2021 | 6 | 1.540 |
Why?
| National Institutes of Health (U.S.) | 2 | 2021 | 49 | 1.540 |
Why?
| Poverty | 3 | 2020 | 231 | 1.490 |
Why?
| Quality of Life | 12 | 2023 | 924 | 1.490 |
Why?
| Clothing | 2 | 2020 | 6 | 1.480 |
Why?
| Patient Selection | 3 | 2020 | 284 | 1.460 |
Why?
| Lipids | 3 | 2022 | 178 | 1.460 |
Why?
| Prescription Drugs | 2 | 2020 | 35 | 1.440 |
Why?
| Cosmetics | 2 | 2020 | 5 | 1.430 |
Why?
| Marketing | 4 | 2022 | 27 | 1.370 |
Why?
| Dermatologic Surgical Procedures | 2 | 2019 | 38 | 1.360 |
Why?
| Fluorouracil | 2 | 2019 | 61 | 1.360 |
Why?
| Erythema | 5 | 2020 | 49 | 1.330 |
Why?
| Urticaria | 4 | 2021 | 24 | 1.300 |
Why?
| Immunologic Factors | 5 | 2021 | 130 | 1.300 |
Why?
| Antibodies, Monoclonal | 6 | 2022 | 564 | 1.280 |
Why?
| Biomedical Research | 2 | 2021 | 241 | 1.240 |
Why?
| Staphylococcal Infections | 2 | 2021 | 302 | 1.220 |
Why?
| Pain | 7 | 2022 | 405 | 1.200 |
Why?
| Consumer Health Information | 3 | 2021 | 21 | 1.190 |
Why?
| Diet | 4 | 2023 | 598 | 1.170 |
Why?
| United States | 15 | 2023 | 5208 | 1.130 |
Why?
| Social Class | 4 | 2020 | 109 | 1.090 |
Why?
| Administration, Cutaneous | 8 | 2020 | 63 | 1.070 |
Why?
| Lichen Planus | 2 | 2018 | 8 | 1.060 |
Why?
| Cost of Illness | 3 | 2020 | 132 | 1.050 |
Why?
| Epidermis | 3 | 2023 | 31 | 1.040 |
Why?
| Skin Physiological Phenomena | 4 | 2018 | 19 | 1.020 |
Why?
| Adult | 27 | 2023 | 14207 | 1.010 |
Why?
| Alopecia Areata | 2 | 2021 | 6 | 1.010 |
Why?
| Patient Participation | 3 | 2021 | 68 | 0.970 |
Why?
| Pediatrics | 2 | 2022 | 323 | 0.960 |
Why?
| Female | 34 | 2023 | 28471 | 0.960 |
Why?
| Genetic Predisposition to Disease | 2 | 2017 | 570 | 0.940 |
Why?
| Periodicals as Topic | 2 | 2021 | 65 | 0.940 |
Why?
| Treatment Outcome | 14 | 2024 | 5612 | 0.930 |
Why?
| Skin Neoplasms | 3 | 2019 | 532 | 0.900 |
Why?
| Paraneoplastic Syndromes | 2 | 2020 | 24 | 0.890 |
Why?
| Sebaceous Gland Diseases | 2 | 2020 | 2 | 0.880 |
Why?
| Eye Diseases | 1 | 2023 | 35 | 0.880 |
Why?
| Baths | 2 | 2019 | 6 | 0.870 |
Why?
| Administration, Topical | 5 | 2021 | 71 | 0.850 |
Why?
| Anxiety | 4 | 2021 | 279 | 0.840 |
Why?
| Product Labeling | 2 | 2018 | 6 | 0.840 |
Why?
| Pyoderma Gangrenosum | 1 | 2021 | 8 | 0.830 |
Why?
| Drug Substitution | 1 | 2021 | 11 | 0.820 |
Why?
| Hidradenitis | 1 | 2021 | 1 | 0.820 |
Why?
| Health Knowledge, Attitudes, Practice | 2 | 2019 | 541 | 0.820 |
Why?
| Financing, Government | 1 | 2021 | 25 | 0.820 |
Why?
| Child | 16 | 2024 | 7368 | 0.800 |
Why?
| Biosimilar Pharmaceuticals | 1 | 2021 | 3 | 0.800 |
Why?
| Medicare Part B | 1 | 2021 | 6 | 0.790 |
Why?
| Students, Medical | 3 | 2020 | 178 | 0.790 |
Why?
| Interleukin-4 | 4 | 2014 | 48 | 0.780 |
Why?
| Acute Generalized Exanthematous Pustulosis | 1 | 2020 | 1 | 0.780 |
Why?
| Th2 Cells | 1 | 2021 | 26 | 0.780 |
Why?
| Diagnostic Errors | 1 | 2021 | 74 | 0.780 |
Why?
| Th17 Cells | 1 | 2021 | 26 | 0.770 |
Why?
| Th1 Cells | 1 | 2021 | 50 | 0.770 |
Why?
| Bedding and Linens | 1 | 2020 | 1 | 0.770 |
Why?
| Textiles | 1 | 2020 | 3 | 0.770 |
Why?
| Spouses | 1 | 2020 | 13 | 0.770 |
Why?
| Darier Disease | 1 | 2020 | 3 | 0.760 |
Why?
| Biological Factors | 2 | 2019 | 13 | 0.760 |
Why?
| Endocannabinoids | 2 | 2019 | 28 | 0.760 |
Why?
| Biopsy | 4 | 2020 | 692 | 0.750 |
Why?
| Patients | 2 | 2023 | 53 | 0.750 |
Why?
| Neurodermatitis | 1 | 2020 | 2 | 0.740 |
Why?
| Foundations | 1 | 2020 | 19 | 0.740 |
Why?
| Ophthalmology | 1 | 2021 | 40 | 0.740 |
Why?
| Prurigo | 1 | 2020 | 7 | 0.740 |
Why?
| Aged | 14 | 2021 | 10060 | 0.740 |
Why?
| Pituitary-Adrenal System | 1 | 2020 | 23 | 0.730 |
Why?
| Awards and Prizes | 1 | 2020 | 20 | 0.730 |
Why?
| Drug Costs | 1 | 2020 | 35 | 0.730 |
Why?
| Male | 26 | 2022 | 27347 | 0.730 |
Why?
| Hypothalamo-Hypophyseal System | 1 | 2020 | 28 | 0.730 |
Why?
| Staphylococcus aureus | 2 | 2021 | 363 | 0.720 |
Why?
| Immune System | 1 | 2020 | 49 | 0.710 |
Why?
| Biological Therapy | 1 | 2019 | 18 | 0.700 |
Why?
| Sexual Behavior | 1 | 2020 | 126 | 0.700 |
Why?
| Arthritis, Rheumatoid | 1 | 2020 | 130 | 0.700 |
Why?
| Physician-Patient Relations | 2 | 2020 | 134 | 0.700 |
Why?
| Patient Care | 1 | 2019 | 65 | 0.700 |
Why?
| Tacrolimus | 3 | 2020 | 52 | 0.700 |
Why?
| Audiovisual Aids | 1 | 2019 | 15 | 0.690 |
Why?
| Young Adult | 11 | 2021 | 4318 | 0.690 |
Why?
| Health Care Costs | 1 | 2020 | 175 | 0.690 |
Why?
| Critical Pathways | 1 | 2019 | 36 | 0.690 |
Why?
| Hand Dermatoses | 1 | 2019 | 8 | 0.690 |
Why?
| Trace Elements | 1 | 2019 | 13 | 0.690 |
Why?
| Adolescent | 13 | 2023 | 6900 | 0.690 |
Why?
| Sleep Initiation and Maintenance Disorders | 1 | 2019 | 43 | 0.690 |
Why?
| Body Water | 1 | 2019 | 34 | 0.690 |
Why?
| Minerals | 1 | 2019 | 36 | 0.690 |
Why?
| Sebaceous Glands | 2 | 2016 | 12 | 0.690 |
Why?
| Sebum | 2 | 2015 | 2 | 0.680 |
Why?
| Quality of Health Care | 1 | 2021 | 219 | 0.680 |
Why?
| Nutrigenomics | 1 | 2018 | 4 | 0.680 |
Why?
| Anti-Bacterial Agents | 4 | 2023 | 825 | 0.680 |
Why?
| Computer-Assisted Instruction | 1 | 2019 | 41 | 0.680 |
Why?
| Preoperative Period | 1 | 2019 | 59 | 0.680 |
Why?
| Acneiform Eruptions | 1 | 2018 | 1 | 0.680 |
Why?
| Indians, North American | 1 | 2019 | 38 | 0.680 |
Why?
| Vitamins | 1 | 2019 | 72 | 0.670 |
Why?
| Sun Protection Factor | 1 | 2018 | 1 | 0.670 |
Why?
| Medication Adherence | 1 | 2020 | 133 | 0.660 |
Why?
| Sodium Hypochlorite | 1 | 2018 | 3 | 0.660 |
Why?
| Alopecia | 1 | 2019 | 59 | 0.660 |
Why?
| Disinfectants | 1 | 2018 | 12 | 0.650 |
Why?
| Dietary Supplements | 2 | 2019 | 457 | 0.650 |
Why?
| Pharmacies | 1 | 2019 | 63 | 0.650 |
Why?
| Pharmacy | 1 | 2019 | 64 | 0.650 |
Why?
| Education, Medical, Undergraduate | 1 | 2019 | 84 | 0.650 |
Why?
| Carcinoma, Squamous Cell | 1 | 2022 | 385 | 0.650 |
Why?
| Chronotherapy | 1 | 2017 | 3 | 0.640 |
Why?
| Medicine, Traditional | 1 | 2018 | 18 | 0.640 |
Why?
| Plant Oils | 1 | 2018 | 18 | 0.640 |
Why?
| Nutritional Status | 1 | 2019 | 158 | 0.640 |
Why?
| Health Resources | 4 | 2022 | 80 | 0.630 |
Why?
| Sweat | 1 | 2017 | 7 | 0.630 |
Why?
| Sweating | 1 | 2017 | 19 | 0.630 |
Why?
| Skin Diseases, Papulosquamous | 1 | 2017 | 2 | 0.630 |
Why?
| Artificial Intelligence | 1 | 2019 | 85 | 0.630 |
Why?
| Water | 2 | 2023 | 103 | 0.630 |
Why?
| Pseudoxanthoma Elasticum | 1 | 2017 | 6 | 0.630 |
Why?
| Diagnosis, Differential | 6 | 2020 | 1141 | 0.620 |
Why?
| Programmed Cell Death 1 Receptor | 1 | 2018 | 40 | 0.620 |
Why?
| Bibliometrics | 6 | 2023 | 24 | 0.620 |
Why?
| Paternal Exposure | 1 | 2017 | 6 | 0.620 |
Why?
| Circadian Rhythm | 1 | 2017 | 85 | 0.610 |
Why?
| Physicians | 1 | 2021 | 245 | 0.600 |
Why?
| Maternal Behavior | 1 | 2017 | 33 | 0.600 |
Why?
| Retinoids | 2 | 2023 | 9 | 0.600 |
Why?
| Skin Diseases, Eczematous | 1 | 2017 | 1 | 0.600 |
Why?
| Internet | 5 | 2022 | 275 | 0.600 |
Why?
| Cannabinoid Receptor Modulators | 1 | 2017 | 13 | 0.590 |
Why?
| Lung Neoplasms | 2 | 2020 | 643 | 0.580 |
Why?
| Maternal Exposure | 1 | 2017 | 87 | 0.580 |
Why?
| Costs and Cost Analysis | 3 | 2022 | 109 | 0.580 |
Why?
| Health Status Disparities | 1 | 2018 | 219 | 0.550 |
Why?
| Middle Aged | 13 | 2021 | 13082 | 0.540 |
Why?
| Aminoquinolines | 1 | 2015 | 11 | 0.540 |
Why?
| Interleukin-2 | 1 | 2015 | 75 | 0.530 |
Why?
| Renal Insufficiency, Chronic | 1 | 2018 | 182 | 0.520 |
Why?
| Melanoma | 2 | 2015 | 313 | 0.510 |
Why?
| Lip Diseases | 1 | 2014 | 2 | 0.510 |
Why?
| Lentigo | 1 | 2014 | 4 | 0.510 |
Why?
| Up-Regulation | 3 | 2012 | 509 | 0.500 |
Why?
| Tinea | 1 | 2013 | 3 | 0.480 |
Why?
| Dermatomycoses | 1 | 2013 | 24 | 0.470 |
Why?
| Coloring Agents | 1 | 2013 | 84 | 0.470 |
Why?
| Facial Dermatoses | 3 | 2020 | 11 | 0.460 |
Why?
| Vascular Endothelial Growth Factor C | 1 | 2012 | 3 | 0.450 |
Why?
| Lymphangiogenesis | 1 | 2012 | 5 | 0.440 |
Why?
| Secondary Prevention | 1 | 2013 | 89 | 0.440 |
Why?
| Dermis | 1 | 2012 | 20 | 0.440 |
Why?
| Patch Tests | 2 | 2022 | 9 | 0.430 |
Why?
| Double-Blind Method | 4 | 2024 | 743 | 0.430 |
Why?
| Hydrophobic and Hydrophilic Interactions | 1 | 2012 | 42 | 0.430 |
Why?
| Lichen Nitidus | 1 | 2011 | 1 | 0.420 |
Why?
| Pilot Projects | 3 | 2019 | 807 | 0.420 |
Why?
| Lichenoid Eruptions | 1 | 2011 | 4 | 0.420 |
Why?
| Dermatitis | 2 | 2023 | 42 | 0.400 |
Why?
| Health Education | 1 | 2013 | 178 | 0.400 |
Why?
| Injections, Subcutaneous | 2 | 2022 | 58 | 0.390 |
Why?
| Interleukin-4 Receptor alpha Subunit | 2 | 2021 | 4 | 0.390 |
Why?
| Adjuvants, Immunologic | 2 | 2021 | 61 | 0.380 |
Why?
| United States Food and Drug Administration | 2 | 2022 | 97 | 0.380 |
Why?
| Telemedicine | 3 | 2021 | 453 | 0.370 |
Why?
| Health Personnel | 1 | 2013 | 247 | 0.370 |
Why?
| Macrophages | 1 | 2012 | 404 | 0.350 |
Why?
| Histamine Antagonists | 2 | 2019 | 22 | 0.350 |
Why?
| Neck | 3 | 2020 | 116 | 0.340 |
Why?
| Crohn Disease | 2 | 2020 | 97 | 0.340 |
Why?
| Risk Factors | 4 | 2019 | 3937 | 0.340 |
Why?
| Pemphigus | 2 | 2020 | 14 | 0.340 |
Why?
| Antineoplastic Agents | 1 | 2018 | 1300 | 0.340 |
Why?
| Hygiene | 2 | 2019 | 19 | 0.330 |
Why?
| Vitamin D | 2 | 2019 | 101 | 0.330 |
Why?
| Dermatitis, Seborrheic | 2 | 2020 | 3 | 0.330 |
Why?
| Drug Administration Schedule | 2 | 2019 | 401 | 0.320 |
Why?
| Glucocorticoids | 3 | 2020 | 234 | 0.320 |
Why?
| Single-Blind Method | 3 | 2019 | 120 | 0.320 |
Why?
| Permeability | 2 | 2018 | 87 | 0.310 |
Why?
| Inflammation | 2 | 2023 | 678 | 0.310 |
Why?
| Medicaid | 2 | 2021 | 268 | 0.310 |
Why?
| Practice Guidelines as Topic | 3 | 2020 | 489 | 0.310 |
Why?
| Dose-Response Relationship, Drug | 3 | 2021 | 1476 | 0.310 |
Why?
| Prevalence | 3 | 2020 | 1025 | 0.300 |
Why?
| Boron Compounds | 2 | 2024 | 18 | 0.290 |
Why?
| Recurrence | 2 | 2019 | 692 | 0.290 |
Why?
| Cytokines | 2 | 2022 | 677 | 0.290 |
Why?
| Drug Therapy, Combination | 2 | 2019 | 426 | 0.280 |
Why?
| Depression | 3 | 2020 | 596 | 0.270 |
Why?
| Animals | 9 | 2023 | 14409 | 0.270 |
Why?
| Algorithms | 3 | 2020 | 697 | 0.260 |
Why?
| Neoplasm Staging | 2 | 2020 | 805 | 0.260 |
Why?
| Janus Kinase 1 | 2 | 2017 | 20 | 0.260 |
Why?
| Life Style | 3 | 2023 | 156 | 0.260 |
Why?
| Publishing | 2 | 2021 | 45 | 0.240 |
Why?
| Water Loss, Insensible | 1 | 2023 | 1 | 0.240 |
Why?
| Scalp Dermatoses | 1 | 2023 | 8 | 0.240 |
Why?
| Skin Diseases, Genetic | 1 | 2023 | 11 | 0.240 |
Why?
| STAT6 Transcription Factor | 2 | 2014 | 10 | 0.230 |
Why?
| Infertility | 1 | 2023 | 19 | 0.230 |
Why?
| Tendon Injuries | 1 | 2023 | 21 | 0.230 |
Why?
| Cohort Studies | 2 | 2020 | 1546 | 0.230 |
Why?
| Tendons | 1 | 2023 | 32 | 0.230 |
Why?
| Arizona | 2 | 2021 | 14 | 0.230 |
Why?
| Seasons | 1 | 2023 | 98 | 0.230 |
Why?
| Keratinocytes | 2 | 2014 | 96 | 0.220 |
Why?
| Aged, 80 and over | 3 | 2019 | 3431 | 0.220 |
Why?
| Pharmaceutical Vehicles | 1 | 2022 | 6 | 0.220 |
Why?
| Sterol Regulatory Element Binding Protein 1 | 1 | 2022 | 16 | 0.220 |
Why?
| Metformin | 1 | 2023 | 66 | 0.220 |
Why?
| Receptors, Aryl Hydrocarbon | 1 | 2022 | 29 | 0.210 |
Why?
| Academic Medical Centers | 2 | 2020 | 146 | 0.210 |
Why?
| Hyperhidrosis | 1 | 2021 | 3 | 0.210 |
Why?
| Dermatitis, Phototoxic | 1 | 2021 | 2 | 0.210 |
Why?
| Botulinum Toxins, Type A | 1 | 2021 | 14 | 0.210 |
Why?
| Financing, Organized | 1 | 2021 | 14 | 0.210 |
Why?
| Journal Impact Factor | 1 | 2021 | 10 | 0.210 |
Why?
| Pregnancy | 5 | 2023 | 2639 | 0.210 |
Why?
| Symbiosis | 1 | 2021 | 11 | 0.200 |
Why?
| NF-E2-Related Factor 2 | 1 | 2022 | 63 | 0.200 |
Why?
| Leishmania | 1 | 2021 | 7 | 0.200 |
Why?
| Molecular Targeted Therapy | 2 | 2020 | 128 | 0.200 |
Why?
| Pityriasis Rubra Pilaris | 1 | 2021 | 2 | 0.200 |
Why?
| Photochemotherapy | 1 | 2021 | 37 | 0.200 |
Why?
| Child, Preschool | 4 | 2024 | 4158 | 0.200 |
Why?
| Leishmaniasis, Cutaneous | 1 | 2021 | 17 | 0.200 |
Why?
| Self-Help Groups | 1 | 2021 | 16 | 0.200 |
Why?
| Chilblains | 1 | 2020 | 1 | 0.200 |
Why?
| Skin Diseases, Viral | 1 | 2020 | 2 | 0.200 |
Why?
| Cross-Over Studies | 1 | 2021 | 250 | 0.190 |
Why?
| Eye | 1 | 2021 | 36 | 0.190 |
Why?
| Mycobacterium marinum | 1 | 2020 | 4 | 0.190 |
Why?
| Sulfonamides | 1 | 2022 | 146 | 0.190 |
Why?
| Herpes Zoster | 1 | 2020 | 15 | 0.190 |
Why?
| Vulnerable Populations | 1 | 2020 | 44 | 0.190 |
Why?
| Health Care Surveys | 1 | 2021 | 195 | 0.190 |
Why?
| Cross-Sectional Studies | 2 | 2023 | 1696 | 0.190 |
Why?
| Herpes Simplex | 1 | 2020 | 24 | 0.190 |
Why?
| Laurates | 1 | 2020 | 2 | 0.190 |
Why?
| Monoglycerides | 1 | 2020 | 2 | 0.190 |
Why?
| Acantholysis | 1 | 2020 | 10 | 0.190 |
Why?
| Pyrimidines | 1 | 2022 | 196 | 0.190 |
Why?
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 1 | 0.190 |
Why?
| Bacterial Vaccines | 1 | 2020 | 16 | 0.190 |
Why?
| Dermatitis, Perioral | 1 | 2020 | 1 | 0.190 |
Why?
| Surface-Active Agents | 1 | 2020 | 13 | 0.190 |
Why?
| Statistics, Nonparametric | 1 | 2021 | 232 | 0.190 |
Why?
| Virulence Factors | 1 | 2021 | 94 | 0.190 |
Why?
| Mycobacterium Infections, Nontuberculous | 1 | 2020 | 19 | 0.190 |
Why?
| Disease Management | 2 | 2020 | 184 | 0.190 |
Why?
| Exanthema | 1 | 2020 | 36 | 0.190 |
Why?
| Diterpenes | 1 | 2020 | 32 | 0.190 |
Why?
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 22 | 0.190 |
Why?
| Social Isolation | 1 | 2020 | 29 | 0.190 |
Why?
| Coronavirus | 1 | 2020 | 16 | 0.180 |
Why?
| Vegetables | 1 | 2020 | 74 | 0.180 |
Why?
| Communication | 1 | 2022 | 265 | 0.180 |
Why?
| Face | 1 | 2020 | 66 | 0.180 |
Why?
| Isotretinoin | 1 | 2019 | 9 | 0.180 |
Why?
| Infection Control | 1 | 2020 | 58 | 0.180 |
Why?
| Friction | 1 | 2019 | 4 | 0.180 |
Why?
| Drug Compounding | 1 | 2019 | 28 | 0.180 |
Why?
| Massage | 1 | 2019 | 7 | 0.180 |
Why?
| Serotonin Antagonists | 1 | 2019 | 31 | 0.180 |
Why?
| Insurance, Health | 1 | 2020 | 132 | 0.180 |
Why?
| Primary Health Care | 1 | 2023 | 398 | 0.180 |
Why?
| Internship and Residency | 3 | 2020 | 501 | 0.180 |
Why?
| Antidepressive Agents, Tricyclic | 1 | 2019 | 32 | 0.180 |
Why?
| Melatonin | 1 | 2019 | 15 | 0.180 |
Why?
| Insurance Coverage | 1 | 2020 | 108 | 0.180 |
Why?
| Bifidobacterium | 1 | 2019 | 6 | 0.180 |
Why?
| Lactobacillaceae | 1 | 2019 | 2 | 0.180 |
Why?
| Fatigue | 1 | 2020 | 128 | 0.180 |
Why?
| Streptococcus | 1 | 2019 | 15 | 0.180 |
Why?
| Selenium | 1 | 2019 | 9 | 0.180 |
Why?
| Protective Clothing | 1 | 2019 | 8 | 0.180 |
Why?
| Avitaminosis | 1 | 2019 | 4 | 0.170 |
Why?
| Clobetasol | 1 | 2019 | 3 | 0.170 |
Why?
| Drug Administration Routes | 1 | 2019 | 13 | 0.170 |
Why?
| Vitamin B 12 | 1 | 2019 | 28 | 0.170 |
Why?
| Tumor Necrosis Factor-alpha | 2 | 2020 | 435 | 0.170 |
Why?
| Pain Management | 1 | 2020 | 155 | 0.170 |
Why?
| Fruit | 1 | 2020 | 144 | 0.170 |
Why?
| Emulsions | 1 | 2019 | 27 | 0.170 |
Why?
| Central Nervous System Depressants | 1 | 2019 | 78 | 0.170 |
Why?
| Drug Approval | 1 | 2019 | 47 | 0.170 |
Why?
| Benzodiazepines | 1 | 2019 | 70 | 0.170 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2019 | 122 | 0.170 |
Why?
| Stress, Mechanical | 1 | 2019 | 96 | 0.170 |
Why?
| Antipruritics | 1 | 2018 | 6 | 0.170 |
Why?
| Cadaver | 1 | 2019 | 113 | 0.170 |
Why?
| Drugs, Investigational | 1 | 2018 | 17 | 0.170 |
Why?
| Hypnotics and Sedatives | 1 | 2019 | 74 | 0.170 |
Why?
| Vesico-Ureteral Reflux | 1 | 2018 | 15 | 0.170 |
Why?
| Consensus | 1 | 2019 | 157 | 0.170 |
Why?
| Sleep | 1 | 2020 | 188 | 0.170 |
Why?
| Zinc | 1 | 2019 | 59 | 0.170 |
Why?
| Vaccination | 1 | 2021 | 298 | 0.170 |
Why?
| Methylprednisolone | 1 | 2018 | 38 | 0.170 |
Why?
| Evidence-Based Medicine | 1 | 2020 | 276 | 0.170 |
Why?
| Clinical Competence | 2 | 2019 | 444 | 0.160 |
Why?
| Postoperative Care | 1 | 2019 | 121 | 0.160 |
Why?
| Stress, Psychological | 1 | 2020 | 270 | 0.160 |
Why?
| Socioeconomic Factors | 1 | 2020 | 639 | 0.160 |
Why?
| Signal Transduction | 3 | 2022 | 1752 | 0.160 |
Why?
| Urinary Tract Infections | 1 | 2018 | 54 | 0.160 |
Why?
| Pain, Postoperative | 1 | 2019 | 160 | 0.160 |
Why?
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2017 | 10 | 0.160 |
Why?
| Head | 1 | 2018 | 78 | 0.160 |
Why?
| Anesthesia | 1 | 2019 | 79 | 0.160 |
Why?
| Receptors, Interleukin-1 | 1 | 2017 | 20 | 0.160 |
Why?
| Retrospective Studies | 6 | 2022 | 6459 | 0.160 |
Why?
| Interleukin-17 | 1 | 2017 | 38 | 0.150 |
Why?
| Minocycline | 1 | 2017 | 18 | 0.150 |
Why?
| Anti-Infective Agents | 1 | 2018 | 111 | 0.150 |
Why?
| Maternal Age | 1 | 2017 | 46 | 0.150 |
Why?
| Reproducibility of Results | 2 | 2018 | 1301 | 0.150 |
Why?
| Antioxidants | 1 | 2019 | 297 | 0.150 |
Why?
| Skin Diseases, Vesiculobullous | 1 | 2017 | 12 | 0.150 |
Why?
| Acetaminophen | 1 | 2020 | 350 | 0.150 |
Why?
| Vision Disorders | 1 | 2017 | 74 | 0.150 |
Why?
| Parents | 1 | 2020 | 346 | 0.150 |
Why?
| Lupus Erythematosus, Systemic | 1 | 2017 | 76 | 0.150 |
Why?
| Mice, Transgenic | 3 | 2014 | 658 | 0.150 |
Why?
| Mental Disorders | 1 | 2021 | 445 | 0.140 |
Why?
| Cicatrix | 1 | 2016 | 43 | 0.140 |
Why?
| Anesthesia, Local | 1 | 2016 | 19 | 0.140 |
Why?
| Needles | 1 | 2016 | 31 | 0.140 |
Why?
| Patient Acceptance of Health Care | 1 | 2019 | 331 | 0.140 |
Why?
| Infant | 2 | 2022 | 3829 | 0.140 |
Why?
| Curriculum | 1 | 2019 | 434 | 0.140 |
Why?
| Lidocaine | 1 | 2016 | 48 | 0.140 |
Why?
| Carcinoma, Non-Small-Cell Lung | 1 | 2018 | 164 | 0.140 |
Why?
| Cyclosporine | 1 | 2016 | 66 | 0.130 |
Why?
| Injections, Intralesional | 1 | 2015 | 38 | 0.130 |
Why?
| Pregnancy Complications | 1 | 2020 | 387 | 0.130 |
Why?
| Melanosis | 1 | 2015 | 5 | 0.130 |
Why?
| Anesthetics, Local | 1 | 2016 | 74 | 0.130 |
Why?
| Skin Aging | 1 | 2015 | 15 | 0.130 |
Why?
| Graft vs Host Disease | 1 | 2016 | 84 | 0.130 |
Why?
| Immunotherapy | 1 | 2017 | 264 | 0.130 |
Why?
| Peptidylprolyl Isomerase | 1 | 2014 | 9 | 0.130 |
Why?
| Interleukins | 1 | 2014 | 39 | 0.130 |
Why?
| Neoplasm Metastasis | 1 | 2015 | 252 | 0.130 |
Why?
| Stem Cell Transplantation | 1 | 2016 | 201 | 0.130 |
Why?
| Neoplasm Invasiveness | 1 | 2015 | 294 | 0.120 |
Why?
| Computer Simulation | 1 | 2015 | 332 | 0.120 |
Why?
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 105 | 0.120 |
Why?
| Potassium Compounds | 1 | 2013 | 2 | 0.120 |
Why?
| Hydroxides | 1 | 2013 | 2 | 0.120 |
Why?
| Azo Compounds | 1 | 2013 | 12 | 0.120 |
Why?
| Comorbidity | 3 | 2021 | 664 | 0.120 |
Why?
| Indicators and Reagents | 1 | 2013 | 42 | 0.120 |
Why?
| Protein Kinase Inhibitors | 1 | 2015 | 216 | 0.120 |
Why?
| Office Visits | 1 | 2013 | 48 | 0.120 |
Why?
| Staining and Labeling | 1 | 2013 | 106 | 0.110 |
Why?
| Ribonuclease, Pancreatic | 1 | 2012 | 2 | 0.110 |
Why?
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2012 | 5 | 0.110 |
Why?
| Chemotaxis | 1 | 2012 | 28 | 0.110 |
Why?
| Chemokine CCL2 | 1 | 2012 | 79 | 0.110 |
Why?
| Vesicular Transport Proteins | 1 | 2012 | 43 | 0.110 |
Why?
| Neovascularization, Physiologic | 1 | 2012 | 72 | 0.110 |
Why?
| Chemokines, CC | 1 | 2012 | 9 | 0.110 |
Why?
| Janus Kinase 2 | 1 | 2012 | 31 | 0.110 |
Why?
| Hydrogen-Ion Concentration | 1 | 2012 | 194 | 0.100 |
Why?
| Adrenal Cortex Hormones | 2 | 2024 | 95 | 0.100 |
Why?
| Education, Medical, Continuing | 1 | 2011 | 79 | 0.100 |
Why?
| Down-Regulation | 1 | 2012 | 388 | 0.100 |
Why?
| Point-of-Care Systems | 2 | 2021 | 71 | 0.090 |
Why?
| Risk Assessment | 1 | 2015 | 1362 | 0.090 |
Why?
| Disease Models, Animal | 2 | 2014 | 1647 | 0.090 |
Why?
| Follow-Up Studies | 1 | 2015 | 2390 | 0.090 |
Why?
| Gene Expression Regulation | 1 | 2014 | 1063 | 0.090 |
Why?
| Cells, Cultured | 1 | 2012 | 1737 | 0.080 |
Why?
| Disease Progression | 2 | 2021 | 915 | 0.080 |
Why?
| Neoplasms | 1 | 2017 | 1322 | 0.070 |
Why?
| Prospective Studies | 2 | 2023 | 2606 | 0.070 |
Why?
| Photography | 2 | 2015 | 39 | 0.070 |
Why?
| Mice | 2 | 2012 | 6428 | 0.060 |
Why?
| Ointments | 1 | 2024 | 9 | 0.060 |
Why?
| Cellulitis | 1 | 2023 | 15 | 0.060 |
Why?
| Flutamide | 1 | 2023 | 2 | 0.060 |
Why?
| Spironolactone | 1 | 2023 | 5 | 0.060 |
Why?
| Finasteride | 1 | 2023 | 9 | 0.060 |
Why?
| Response Elements | 2 | 2014 | 32 | 0.060 |
Why?
| Fertility | 1 | 2023 | 33 | 0.060 |
Why?
| Delphi Technique | 1 | 2023 | 38 | 0.060 |
Why?
| Extracellular Matrix | 1 | 2023 | 111 | 0.050 |
Why?
| Immunoglobulin A | 1 | 2022 | 54 | 0.050 |
Why?
| Aminolevulinic Acid | 1 | 2021 | 10 | 0.050 |
Why?
| Pyrroles | 1 | 2022 | 78 | 0.050 |
Why?
| Skin Absorption | 1 | 2021 | 24 | 0.050 |
Why?
| Africa | 1 | 2021 | 13 | 0.050 |
Why?
| Computer Literacy | 1 | 2020 | 5 | 0.050 |
Why?
| Ecosystem | 1 | 2021 | 90 | 0.050 |
Why?
| Decision Trees | 1 | 2020 | 26 | 0.050 |
Why?
| Groin | 1 | 2020 | 16 | 0.050 |
Why?
| Skin Cream | 1 | 2020 | 1 | 0.050 |
Why?
| Personnel Selection | 1 | 2020 | 28 | 0.050 |
Why?
| Promoter Regions, Genetic | 2 | 2014 | 520 | 0.050 |
Why?
| Gene Expression | 2 | 2014 | 664 | 0.050 |
Why?
| Mite Infestations | 1 | 2020 | 2 | 0.050 |
Why?
| Malassezia | 1 | 2020 | 6 | 0.050 |
Why?
| Asia | 1 | 2020 | 32 | 0.050 |
Why?
| Hypersensitivity, Immediate | 1 | 2020 | 13 | 0.050 |
Why?
| Axilla | 1 | 2020 | 101 | 0.050 |
Why?
| Family Relations | 1 | 2020 | 25 | 0.050 |
Why?
| Phylogeny | 1 | 2021 | 269 | 0.050 |
Why?
| Delayed Diagnosis | 1 | 2020 | 25 | 0.050 |
Why?
| Breast | 1 | 2020 | 92 | 0.050 |
Why?
| Pilonidal Sinus | 1 | 2019 | 1 | 0.050 |
Why?
| Women's Health | 1 | 2020 | 107 | 0.050 |
Why?
| Interpersonal Relations | 1 | 2020 | 115 | 0.050 |
Why?
| Interleukin-23 | 1 | 2019 | 10 | 0.040 |
Why?
| Specialties, Surgical | 1 | 2020 | 38 | 0.040 |
Why?
| Gynecology | 1 | 2020 | 50 | 0.040 |
Why?
| Odds Ratio | 1 | 2021 | 600 | 0.040 |
Why?
| Immunocompromised Host | 1 | 2020 | 130 | 0.040 |
Why?
| Models, Biological | 1 | 2023 | 825 | 0.040 |
Why?
| Needs Assessment | 1 | 2020 | 153 | 0.040 |
Why?
| Physicians, Primary Care | 1 | 2019 | 43 | 0.040 |
Why?
| Patient Care Planning | 1 | 2020 | 79 | 0.040 |
Why?
| Activities of Daily Living | 1 | 2020 | 204 | 0.040 |
Why?
| Postpartum Period | 1 | 2020 | 117 | 0.040 |
Why?
| Outpatients | 1 | 2020 | 122 | 0.040 |
Why?
| Substance Withdrawal Syndrome | 1 | 2020 | 179 | 0.040 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 142 | 0.040 |
Why?
| Aspirin | 1 | 2020 | 127 | 0.040 |
Why?
| Obstetrics | 1 | 2020 | 89 | 0.040 |
Why?
| Hemorrhage | 1 | 2020 | 209 | 0.040 |
Why?
| Image Processing, Computer-Assisted | 1 | 2020 | 256 | 0.040 |
Why?
| Breast Feeding | 1 | 2020 | 191 | 0.040 |
Why?
| Psychiatry | 1 | 2020 | 116 | 0.040 |
Why?
| Patient Care Team | 1 | 2020 | 273 | 0.040 |
Why?
| Case-Control Studies | 1 | 2021 | 1229 | 0.040 |
Why?
| Mental Health | 1 | 2020 | 245 | 0.040 |
Why?
| Aging | 1 | 2023 | 784 | 0.040 |
Why?
| Pemphigoid, Bullous | 1 | 2017 | 10 | 0.040 |
Why?
| Mucous Membrane | 1 | 2017 | 33 | 0.040 |
Why?
| Mental Health Services | 1 | 2020 | 233 | 0.040 |
Why?
| Atrophy | 1 | 2016 | 40 | 0.040 |
Why?
| Rats | 1 | 2023 | 3419 | 0.040 |
Why?
| Observer Variation | 1 | 2016 | 139 | 0.030 |
Why?
| Mitogen-Activated Protein Kinase Kinases | 1 | 2015 | 39 | 0.030 |
Why?
| Autoimmune Diseases | 1 | 2017 | 115 | 0.030 |
Why?
| Secretory Rate | 1 | 2015 | 4 | 0.030 |
Why?
| Forehead | 1 | 2015 | 10 | 0.030 |
Why?
| Biometry | 1 | 2015 | 28 | 0.030 |
Why?
| Infant, Newborn | 1 | 2023 | 2923 | 0.030 |
Why?
| Emergency Service, Hospital | 1 | 2019 | 543 | 0.030 |
Why?
| Hospitalization | 1 | 2019 | 704 | 0.030 |
Why?
| Janus Kinases | 1 | 2014 | 8 | 0.030 |
Why?
| Cell Line, Transformed | 1 | 2014 | 88 | 0.030 |
Why?
| Image Interpretation, Computer-Assisted | 1 | 2015 | 119 | 0.030 |
Why?
| Genes, Reporter | 1 | 2014 | 98 | 0.030 |
Why?
| Imaging, Three-Dimensional | 1 | 2015 | 172 | 0.030 |
Why?
| Obesity | 1 | 2023 | 1203 | 0.030 |
Why?
| Time Factors | 1 | 2020 | 3210 | 0.030 |
Why?
| Antimicrobial Cationic Peptides | 1 | 2012 | 31 | 0.030 |
Why?
| Tyrphostins | 1 | 2012 | 16 | 0.030 |
Why?
| Active Transport, Cell Nucleus | 1 | 2012 | 45 | 0.030 |
Why?
| Inflammation Mediators | 1 | 2012 | 128 | 0.030 |
Why?
| Luciferases | 1 | 2012 | 57 | 0.030 |
Why?
| Cell Nucleus | 1 | 2012 | 203 | 0.020 |
Why?
| Blotting, Western | 1 | 2012 | 684 | 0.020 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 674 | 0.020 |
Why?
| Phosphorylation | 1 | 2012 | 613 | 0.020 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 1060 | 0.020 |
Why?
| Enzyme Inhibitors | 1 | 2012 | 446 | 0.020 |
Why?
| Immunohistochemistry | 1 | 2012 | 1090 | 0.020 |
Why?
| Cell Line | 1 | 2012 | 1152 | 0.020 |
Why?
| Mutation | 1 | 2014 | 1504 | 0.020 |
Why?
|
|
Shi's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|